Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report.
Aged
Antibodies, Monoclonal, Humanized
/ administration & dosage
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Immunological
Carcinoma, Squamous Cell
/ drug therapy
Cisplatin
/ administration & dosage
Deoxycytidine
/ administration & dosage
Drug Therapy, Combination
Humans
Lung Neoplasms
/ drug therapy
Magnesium
/ therapeutic use
Magnesium Deficiency
/ chemically induced
Male
Gemcitabine
cisplatin
gemcitabine
hypomagnesemia
necitumumab
squamous cell lung cancer
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
revised:
26
04
2021
received:
05
04
2021
accepted:
27
04
2021
pubmed:
2
6
2021
medline:
17
12
2021
entrez:
1
6
2021
Statut:
ppublish
Résumé
A 72-year-old man, diagnosed with advanced lung squamous cell carcinoma, was administered of cisplatin plus gemcitabine with necitumumab, a human monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), as a sixth-line treatment. Tumor shrinkage was observed, but asymptomatic grade 4 hypomagnesemia occurred on day 8 of the second cycle. He received magnesium replenishment and hypomagnesemia recovered on day 40, but tumor progression was observed during the period of magnesium correction. Hypomagnesemia is known as a major adverse event of treatment with anti-EGFR antibodies, but there have been no case reports of severe hypomagnesemia or its clinical course.
Identifiants
pubmed: 34061460
doi: 10.1111/1759-7714.13999
pmc: PMC8258358
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antimetabolites, Antineoplastic
0
Antineoplastic Agents
0
Antineoplastic Agents, Immunological
0
Deoxycytidine
0W860991D6
necitumumab
2BT4C47RUI
Magnesium
I38ZP9992A
Cisplatin
Q20Q21Q62J
Gemcitabine
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
2039-2042Informations de copyright
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Lung Cancer. 2019 Mar;129:55-62
pubmed: 30797492
N Engl J Med. 2020 Aug 13;383(7):640-649
pubmed: 32786189
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Front Oncol. 2016 Sep 14;6:196
pubmed: 27683640
Thorac Cancer. 2021 Jul;12(13):2039-2042
pubmed: 34061460
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Sci Rep. 2018 Feb 1;8(1):2047
pubmed: 29391418
N Engl J Med. 2009 Apr 2;360(14):1408-17
pubmed: 19339720
Int J Nephrol Renovasc Dis. 2014 Jun 09;7:219-30
pubmed: 24966690
Expert Opin Drug Saf. 2015 Jun;14(6):795-800
pubmed: 25851664
Yakugaku Zasshi. 2017;137(1):79-82
pubmed: 28049899
J Am Soc Nephrol. 2007 Oct;18(10):2649-52
pubmed: 17804670
Lancet Oncol. 2015 Jul;16(7):763-74
pubmed: 26045340
J Clin Oncol. 2007 May 1;25(13):1658-64
pubmed: 17470858